Library — CHDR

Search

Filter

A smartphone- and wearable-based biomarker for the estimation of unipolar depression severity.

Zhuparris A, Maleki G, van Londen L, Koopmans I, Aalten V, Yocarini IE, Exadaktylos V, van Hemert A, Cohen A, Gal P, Doll RJ, Groeneveld GJ, Jacobs G, Kraaij W

Scientific reports, 2023 Nov; 13(1):18844

View publication
Item response theory in early phase clinical trials: Utilization of a reference model to analyze the Montgomery-Åsberg Depression Rating Scale.

Otto ME, Bergmann KR, de Kam ML, Recourt K, Jacobs GE, van Esdonk MJ

CPT: pharmacometrics & systems pharmacology, 2023 Aug

View publication
Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder.

Recourt K, de Boer P, van der Ark P, Benes H, van Gerven JMA, Ceusters M, van Nueten L, Drevets WC, Bhatacharya A, Browning M, Jacobs GE

Translational psychiatry, 2023 Jul; 13(1):266

View publication
Cognitive performance in healthy clinical trial participants and patients with the NeuroCart, a neurodegenerative disease measured with an automated neuropsychological and neurophysiological test battery.

Prins S, Borghans L, de Kam ML, Groeneveld GJ, van Gerven J

Journal of the neurological sciences, 2023 Jun

View publication
Decreased integrity of the monoaminergic tract is associated with a positive response to MPH in patients with vascular cognitive impairment - proof of principle study STREAM-VCI.

Leijenaar JF, Ingala S, Sudre CH, Mutsaerts HM, Leeuwis AE, van der Flier WM, Scheltens P, Weinstein HC, Barkhof F, van Gerven J, Groeneveld GJ, Prins ND

Cerebral circulation - cognition and behavior, 2023 May

View publication
Pharmacological characterization of the selective orexin-1 receptor antagonist JNJ-61393215 in healthy volunteers.

Brooks S, Zuiker R, Bleys C, Ziagkos D, Moyer JA, van Nueten L, Bonaventure P, Drevets WC, van Gerven J, Salvadore G, Jacobs GE

Journal of psychopharmacology (Oxford, England), 2023 May

View publication
Translatability of preclinical to early clinical tolerable and pharmacologically active dose ranges for central nervous system active drugs.

Ferreira GS, Dijkstra FM, Veening-Griffioen DH, Boon WPC, Schellekens H, Moors EHM, van Meer PJK, Stuurman FE, van Gerven JMA

Translational psychiatry, 2023 Mar; 13(1):74

View publication
Repeated intravenous esketamine treatment in patients with ECT-resistant major depressive disorder

A. Safai Pour a b 1, S.J.M. van der Aalst a 1, I.J. Brouwer a, E.J. Giltay a, G.E. Jacobs a b, N.J.A. van der Wee a, A.M. van Hemert a, M.S. van Noorden

Journal of Affective Disorders Reports Volume 10, December 2022, 100400, 2022 Dec

View publication
Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration-effect relations using the IB-de-risk tool.

Kwee CM, van Gerven JM, Bongaerts FL, Cath DC, Jacobs G, Baas JM, Groenink L

Journal of psychopharmacology (Oxford, England), 2022 Dec; 36(12):1299-1314

View publication

«
1
2
3
4
5
6
7
8
...
13
14
»